The E1A-targeted transcription factor E4F1 is a key player in the control of mammalian embryonic and somatic cell proliferation and survival. Mouse embryos lacking E4F die at an early developmental stage, whereas enforced expression of E4F1 in various cell lines inhibits cell cycle progression. E4F1-antiproliferative effects have been shown to depend on its capacity to repress transcription and to interact with pRb and p53. Here we show that full-length E4F1 protein (p120 E4F1 ) but not its E1A-activated and truncated form (p50 E4F1 ), interacts directly in vitro and in vivo with the LIM-only protein FHL2, the product of the p53-responsive gene FHL2/ DRAL (downregulated in rhabdomyosarcoma Lim protein). This E4F1-FHL2 association occurs in the nuclear compartment and inhibits the capacity of E4F1 to block cell proliferation. Consistent with this effect, ectopic expression of FHL2 inhibits E4F1 repressive effects on transcription and correlates with a reduction of nuclear E4F1-p53 complexes. Overall, these results suggest that FHL2/DRAL is an inhibitor of E4F1 activity. Finally, we show that endogenous E4F1-FHL2 complexes form in U2OS cells upon UV-light-induced nuclear accumulation of FHL2.
Introduction
The mammalian transcriptional activity termed E4F was first described as one of the cellular targets of the viral oncoprotein E1A, which activation is required for full expression of the viral E4 promoter during adenovirus infection (Raychaudhuri et al., 1987) . This E4F activity was purified from human cells and shown to be carried out by a GLI/Kruppel-related 50 kDa transcription factor (p50
E4F1
) generated, upon an E1A-activated proteolytic cleavage, from the ubiquitously expressed 120 kDa protein (p120
) (Fernandes et al., 1997) previously identified in mouse as PhiAP3 (Fognani et al., 1993) . Although both p50
E4F1 and p120
recognize the same DNA motives in vitro, they appear to differentially regulate gene expression in vivo. p50
transactivates expression of the adenoviral E4 gene through multiple CRE-like elements in an E1A-dependent fashion (Fernandes et al., 1997) . On the contrary, p120
, at least when overexpressed, is likely to play a role of repressor for the adenoviral E4 and E1A promoters (Fognani et al., 1993; Fernandes et al., 1997) and for the cellular cyclin A2 gene (Fajas et al., 2001; Tessari et al., 2003; Ahmed-Choudhury et al., 2005) , a property that might rely on its direct interaction with histone deacetylase 1 (Colombo et al., 2003) .
The precise function of E4F1 in normal cell physiology remains largely unknown. Nevertheless, several recent observations demonstrate it is a key player in the control of mammalian embryonic and somatic cell proliferation and survival. Indeed, embryos lacking E4F1 die at the peri-implantation stage, while in vitro cultured E4F À/À blastocysts exhibit severe defects in mitotic progression, chromosomal missegregation and increased apoptosis (Le Cam et al., 2004) . Conversely, enforced expression of p120 E4F1 in various cell lines inhibits progression from G1 to S phase (Fernandes et al., 1998; Fajas et al., 2000 Fajas et al., , 2001 Sandy et al., 2000; Rizos et al., 2003; Fenton et al., 2004) and that of p50 E4F1 enhances cell death in E1A/ras-transformed cells (Fernandes et al., 1999) . Interestingly, the E4F1-induced G1 arrest appears to depend, at least in part, on pRB and p53 pathways (Fajas et al., 2000; Sandy et al., 2000; Rizos et al., 2003) . Consistent with this, E4F1 was found to interact directly in vivo with pRB (Fajas et al., 2000) , p53 (Sandy et al., 2000) and p19
ARF (Rizos et al., 2003) and to induce the stabilization of the p21 WAF1 protein (Fernandes et al., 1998) . This suggests that E4F1 is somehow involved in both the pRB and p53 pathways.
To address this question, we searched for novel E4F1-interactors/regulators that might be involved in the pRB/p53 pathways. Here, we show that p120
interacts with the product of the p53-responsive gene downregulated in rhabdomyosarcoma Lim protein (DRAL)/FHL2. This gene was originally identified as the product of the DRAL gene, which expression is downregulated in human rhabdomyosarcoma cells as compared with nonmalignant control myoblasts (Genini et al., 1997) , suggesting a role in tumor development.
DARL/FHL2 is strongly expressed in cardiac and skeletal muscle cells and, at lower levels, in many other tissues, cell types and established cell lines (Chan et al., 1998; Chu et al., 2000a, b; Scholl et al., 2000; Tanahashi and Tabira, 2000; Kong et al., 2001; Muller et al., 2002; Gabriel et al., 2004; Kang et al., 2003) . It encodes a member of the FHL protein family (FHL1-4, ACT), a subclass of the LIM-only protein family, that contains four and an half copies of the cysteine-rich LIM motif (CX2CX16-23HX2CX2CX2CX16-21CX2-3(C/H/D), a widely represented protein domain which functions as an adapter or modifier in protein interactions (Retaux and Bachy, 2002) . Although the cellular functions of these FHL proteins remain largely unknown, recent studies suggest that they may act as transcriptional coregulators and mediators in signal transduction. Thus, upon ectopic expression in reporter assays, FHL2 behaves as a coactivator for several transcription factors, including AP-1 (Morlon and Sassone-Corsi, 2003) , CREB (Fimia et al., 2000) , androgen receptor (Muller et al., 2000) , NF-kB (Stilo et al., 2002) , WT1 (Du et al., 2002) and as a corepressor for the Promyelocytic leukemia zinc-finger protein (PLZF) (McLoughlin et al., 2002) . Interestingly, DRAL/FHL2 was also described to directly associates with proteins involved in signal transduction, such as IGFBP-5 (Amaar et al., 2002) , b-catenin (Martin et al., 2002; Wei et al., 2003; Labalette et al., 2004) , a-and bintegrins (Wixler et al., 2000) and the map kinase erk2 (Purcell et al., 2004) , suggesting that it might function as a molecular transmitter linking various signaling pathways to transcriptional regulation. Consistent with this scenario, DRAL/FHL2 cellular localization seems to be both nuclear and non-nuclear (Scholl et al., 2000) . Moreover, it undergoes a Rho-and Crm1-dependent nuclear accumulation in response to various gowth, morphogenic and apoptotic signals (Muller et al., 2002; Morlon and Sassone-Corsi, 2003) . The physiological consequences of this DRAL/FHL2 nuclear accumulation remains unclear and might depend on the cellular context, on the signals that initiates shuttling and on its targets. Nevertheless, overexpression of DRAL/FHL2 in several normal and tumor-derived cell lines efficiently induces an apoptotic program (Scholl et al., 2000) . This proapoptotic property might be physiologically relevant since endogenous DRAL/FHL2 gene contains p53 binding sites in its promoter and is strongly induced by irradiation in a p53-dependent manner with kinetics similar to p21 WAF1 (Scholl et al., 2000) . In the present study, we provide evidence for another link between DRAL/FHL2 and the p53 pathway. We show that DRAL/FHL2 interacts directly with the p53-associated protein p120 E4F1 , but not p50 E4F1 , both in vitro and in vivo. This E4F1-FHL2 association inhibits the capacity of E4F1 to block the cell cycle and correlates with a reduction of nuclear E4F1-p53 complexes and of E4F1 repressive effects on transcription. Association of endogenous E4F1 and FHL2 proteins in U2OS is stimulated by UV, a signal that stimulates expression and nuclear translocation of FHL2 in these cells.
Results
Identification of DARL/FHL2 as a p120 E4F1 interacting protein in vitro and in a cellular context To identify novel E4F1 interaction partners potentially involved in the pRB/p53 pathways, we performed a yeast two-hybrid screen using Gal4DB-p120 E4F1 as a bait to probe a library of Gal4AD-cDNA preys generated from WI38 human primary fibroblasts (Sardet et al., 1995) . Several classes of clones were selected, one corresponding to the p53-responsive gene DRAL/ FHL2. This LIM-only protein was represented by five independent positive clones containing Gal4-DRAL/ FHL2 cDNAs ( Figure 1a) . of various lengths. The longest fusion corresponding to full-length FHL2 and the shortest one to a N-ter truncated version of the protein that contained the last two LIM domains (data not shown).
To confirm this interaction in vitro, we performed glutathione S-transferase (GST) pull-down assays by mixing in vitro translated methionine-labeled p120 E4F and either GST-FHL2 or the control fusion proteins, GST and GST-ELK. As shown in Figure 1b , labeled E4F1 bound specifically to GST-FHL2 beads and not on control beads in this assay. Notably, dialysis of bacterial FHL2 in a buffer containing ZnCl 2 was required in order to get optimum E4F1-FHL2 interaction (data not shown), suggesting that generation of GST-FHL2 in a zinc-finger LIM conformation is, at least in part, important for this interaction.
To document this association in a cellular context, we performed co-immunoprecipitation experiments on various mammalian cell lines transiently co-transfected with expression vectors encoding full-length Flag-tagged FHL2 and E4F1 proteins. The two proteins were efficiently co-immunoprecipitated from cellular extracts prepared from transfected U2OS osteosarcoma cells using either an anti-Flag antibody (Figure 2b and d) or an anti-E4F1 antibody (Figure 2b ). The same results were obtained when similar co-transfection experiments were performed in NIH3T3 mouse fibroblasts or in human rhabdomyosarcoma cell line RDE (data not shown). To map the FHL2 and E4F1 protein regions involved in this interaction, we repeated these coimmunoprecipitation assays on cells transiently expressing similar levels of various truncated FHL2 (Figure 2a and b) and E4F1 (Figure 2c and d) proteins.
As shown in Figure 2b , removal of the first two and an half N-terminal LIM domains did not significantly affect FHL2's capacity to associate with E4F1 in this assay, whereas deletion of the third LIM domain completely abolished formation of the complex. These results were consistent with the presence in the twohybrid screen of a N-ter truncated version of FHL2 and suggest that the E4F1-binding region of FHL2 lies within the third LIM domain.
Notably, removal of the DNA-binding region of E4F1 (DDBD-E4F1 and Gal4-DDBD-E4F1) did not affect its capacity to associate with FHL2 in this assay (Figure 2d ). Conversely, FHL2 was unable to associate with p50 E4F1 , the E1A-activated and C-terminal truncated form of E4F1, which contains a functional DNAbinding domain.
Altogether, these binding assays provide evidence that E4F1 and DRAL/FHL2 can interact directly in vitro and in living cells.
p120
E4F strongly stimulates the nuclear accumulation of downregulated in rhabdomyosarcoma Lim protein/FHL2 FHL2 was shown to localize in several cellular compartments and to undergo a continuous Crm1-dependent nuclear-cytoplasmic shuttling (Muller et al., 2002; Morlon and Sassone-Corsi, 2003) . In contrast, E4F1 was reported to be exclusively nuclear. To confirm that these two proteins associate in a cellular context, we next tested whether they could modify the nuclear-cytoplasmic repartition of each other upon cooverexpression.
As previously described, ectopically expressed E4F1 localized almost exclusively in the nucleus of exponentially growing U2OS cells (Figure 3a ) (Fajas et al., 2000 (Fajas et al., , 2001 .
In contrast, in the absence of E4F1 overexpression, both transfected Flag-tagged FHL2 (Figure 3a , b and c) and endogenous FHL2 proteins (Figure 3d and e), were found predominantly in the cytoplasmic compartment, with less than 15% of the positive cells showing also a clear nuclear staining in indirect immunofluorescence (Figure 3b and e). Notably, co-expression of Flagtagged FHL2 and E4F1 led to a threefold increase in cells showing nuclear FHL2 (Figure 3a and b) . This positive effect of E4F1 overexpression on FHL2 nuclear accumulation was confirmed by Western blot analysis of nuclear and cytoplasmic extracts prepared from transfected cells (Figure 3c ). Importantly, this relocalization of FHL2 upon E4F1 overexpression likely depends on E4F1-FHL2 interaction, since it was not observed with the truncated forms of E4F1 and FHL2 that cannot interact, that is p50 E4F1 ( Figure 3b ) and FHL2DL123 (data not shown).
Altogether, these results suggest that E4F1 recruits FHL2 in the nucleus, and provide further evidence that these two factors interact in a cellular context.
FHL2 antagonizes the p53-dependent antiproliferative effects of E4F1 and impacts on E4F1-p53 complexes
We and others had previously demonstrated that E4F1 overexpression leads to a strong reduction of DNA synthesis, which results from a cell cycle arrest in G1 (Fernandes et al., 1998; Fajas et al., 2000 Fajas et al., , 2001 Sandy et al., 2000) . To evaluate the impact of FHL2 on E4F-mediated growth arrest, we monitored DNA synthesis in asynchronously growing U2OS cells transiently cotransfected with various combinations of E4F1 and Flag-tagged FHL2, together with GFP expressing plasmids. At 16 h after transfection, cells were incubated with bromodeoxyuridine (BrdU) for 8 h. Mav103 yeast strain containing chromosomally integrated reporter genes whose expression is regulated by different Gal4 responsive promoters was transfected with either intact Gal4 or combinations of Gal4DB-E4F1 (Bait, pPC97-p120E4F) with preys TA-FHL2 or TA-DP1 (control) in pPC-86. Yeast growing on permissive plates (SC-Leu-Trp) were selected for reporter activation (GAL1:HIS3-dependent prototrophy) by replica plating on SC-Leu-Trp-His plus 100 mM 3-AT plates. (b) Glutathione S-transferase (GST) pulldown assays.
35
S-labeled in vitro translated full-length E4F1 (p120 E4F1 ) (input) was incubated with similar amounts of either Sepharose-bound GST-FHL2, GST or GST-ELK1 (negative control). Co-immunoprecipitation of full-length E4F1 and 3 Â Flagged-FHL2 deletion constructs (FHL2, DL1, DL1/L2 and DL1/L2/L3) ectopically expressed (CMV-driven expression vectors, PCiNeo) in U2OS cells. One-tenth of the input nuclear extracts were loaded in the two upper panels and probed for the presence of E4F1 and FHL2 as indicated by immunoblotting with an affinity purified rabbit polyclonal antibody (E4F-AD1) and anti-Flag monoclonal antibody (M2), respectively. Nuclear extracts were immunoprecipitated with a mixture of two anti-E4F1 antibodies (E4F-AD1 þ E4F-88) or with anti-Flag antibody coupled to agarose beads as indicated. Anti-Flag and anti-E4F1 precipitates were probed by immunoblotting for the presence of E4F1 and Flagged-FHL2, respectively (lower two panels). (c) Schematic representation of the various E4F1 expression constructs used in (d) and summary of their capacity to bind E4F1. The C2H2 Kru¨ppel-like Zinc-fingers are shown as gray boxes. Gal4DB fusion is indicated as an open box. (d) Co-immunoprecipitation of full-length Flag-tagged FHL2 and pcDNA3-E4F1 deletion constructs (E4F1, p50 E4F1 , DN-E4F1, DDBD-E4F1 and Gal4-DDBD-E4F1) ectopically expressed in U2OS cells. One-tenth of the input nuclear extracts were probed as described for the presence of E4F1 and FHL2 by immunoblotting as described in (b) (upper two panels). Nuclear extracts were immunoprecipitated with anti-Flag antibody and precipitates were probed by immunoblotting for the presence of E4F1 deletions (lower panel).
LIM-only protein FHL2 is a negative regulator of E4F1

C Paul et al FHL2 À/À mouse 3T3 fibroblasts (Figure 4b ). Significantly, we found that E4F1 was more potent in inducing growth-arrest in FHL2
À/À cells than in control WT cells, that is a larger fraction of E4F1-transfected cells were arrested in FHL2 À/À fibroblasts than in control fibroblasts, suggesting that endogenous FHL2 also contributes to antagonize the E4F1-antiproliferative effects (Figure 4b ).
These results, together with those showing that FHL2 accumulates in the nucleus and associates with E4F1 upon co-overexpression, suggest that FHL2 might participate to a pathway that interferes with E4F1-mediated growth controls.
FHL2 inhibits E4F1 repressive activity on transcription
The antiproliferative effects of E4F1 has also been shown to depend, at least in part, on its capacity to inhibit transcription of the cyclin A promoter. To evaluate the impact of FHL2 on E4F1-mediated transcriptional repression, U2OS cells were transfected with luciferase reporter constructs driven by E4F1-responsive promoters, cycA-Luc (Figure 5a ) and E4-TK-Luc (Figure 5b ), together with expression vectors encoding E4F1 and FHL2. In agreement with previous reports, E4F1 alone was found to strongly inhibit expression of these reporters, whereas FHL2 had little effect on their expression. Notably, this E4F1-mediated repression was antagonized upon co-expression of FHL2 but not of FHL2DL123 (Figure 5a and b) . This result suggests that FHL2 is playing the role of an inhibitor for E4F1 rather than acting as a coactivator or a corepressor, a function it displays with several other transcription factors.
As previously described in mouse fibroblasts (Sandy et al., 2000; Rizos et al., 2003) , the antiproliferative effect of E4F1 in U2OS also appears to depend on the presence of Wt p53 gene and of the direct interaction between the E4F1 and p53 proteins. Accordingly, the growth arrest induced by E4F1 overexpression in U2OS cells is sensitive to short hairpin RNA (shRNA)-mediated depletion of endogenous p53 (Figure 4a ) (Brummelkamp et al., 2002) . To investigate the potential impact of FHL2 on E4F1-p53 association in these cells, LIM-only protein FHL2 is a negative regulator of E4F1 C Paul et al we performed co-immunoprecipitation experiments on U2OS cells transiently co-transfected with combinations of expression vectors encoding HA-tagged E4F1, fulllength p53 and flagged-FHL2. As in other cell systems (Sandy et al., 2000; Rizos et al., 2003) , ectopically expressed E4F1 and p53 proteins were efficiently coimmunoprecipitated from U2OS nuclear extracts by an anti-E4F1 antibody (Figure 5c ). However, co-immunoprecipitation of E4F1 and p53 was reproducibly and markedly reduced upon overexpression of FHL2 (Figure 5c ), suggesting that FHL2 interferes with the formation of E4F-p53 nuclear complexes in cells.
Altogether, these data suggest that FHL2, upon its nuclear translocation, targets at least two E4F1 functional properties required for growth arrest, that is its association with p53 and its capacity to repress transcription.
Identification of an endogenous FHL2-E4F1 complex in UV-irradiated U2OS cells
To gain information about the physiological function of this E4F1-FHL2 association, we looked for endogenous E4F1-FHL2 complexes and asked whether their abundance could be regulated. Co-immunoprecipitation experiments were performed with an anti-FHL2 antibody or corresponding preimmune serum on nuclear extracts prepared from U2OS cells (Figure 6a ), which expresses FHL2 and E4F1 (Fajas et al., 2000 (Fajas et al., , 2001 Amaar et al., 2002) . As a negative control, we performed the same experiment in RDE cells that express similar levels of E4F1 (Figure 6b ) but almost undetectable levels of FHL2 (Genini et al., 1997; Scholl et al., 2000) . In exponentially growing cells, we repeatedly failed to detect E4F1 in FHL2 precipitates (Figure 6a ). Considering the data shown in Figure 4e , we wondered whether that this failure might reflect the fact that the pool of nuclear FHL2 was low in these growth conditions. Therefore, we repeated this experiment after exposure of U2OS cells to UV (30 J/m 2 ), a condition, which had been described to stimulate the nuclear translocation of FHL2 in exponentially growing fibroblasts (Morlon and Sassone-Corsi, 2003) . Consistent with this report, we found that FHL2 nuclear accumulation was strongly stimulated 8 h after irradiation of U2OS cells (Figure 6b and c) . Under these conditions, endogenous E4F1 was clearly and specifically detected in the anti-FHL2 immunoprecipitate (Figure 6a ). Importantly, this association was not detected, in similar experiments carried out in RDE cells (Figure 6b ) or upon immunoprecipitation of irradiated-U2OS extracts with preimmune serum (Figure 6a ). These data show that genuine E4F1-FHL2 complexes exist in living cells and suggest that they form upon UV-induced nuclear accumulation of FHL2.
Discussion
Here, we show that the kruppel-type zinc-finger transcription factor E4F1 interacts in vitro and in vivo in the nucleus with DRAL/FHL2, a member of the fourand-a-half LIM domain protein family. Ectopic expression of FHL2 impacts on E4F1-dependent cell cycle arrest and repression of E4F1-responsive promoters, and correlates with a strong reduction of nuclear E4F1-p53 complexes. Conversely, E4F1 is more potent in inducing growth-arrest in FHL2 À/À fibroblasts than in control WT cells. This E4F1-FHL2 interaction occurs upon the translocation of FHL2 into the nucleus and supports the notion that E4F1 biological activity might be inhibited by signals that control the nuclear accumulation of FHL2. Consistent with this hypothesis, we found that UV irradiation of U2OS cells induces the À/À pR 53 and WTpR 53 3T3 mouse fibroblasts were co-transfected with combinations of increasing amounts (100 ng, 300 ng) of full-length E4F1 expression vector alone or with 300 ng of full-length FHL2 expression vector, as indicated. As a marker of cell proliferation, transfected (E4F positive) cells were assessed for BrdU uptake in their DNA by using an anti-BrdUrdspecific Ab. The diagram shows the average of two independent experiments.
LIM-only protein FHL2 is a negative regulator of E4F1
C Paul et al nuclear translocation of endogenous FHL2 and the formation of nuclear E4F1-FHL2 complexes. Although expression of FHL2 is predominantly detected in the heart (Chan et al., 1998) , it has also been observed in several extracardiac tissues at certain stages of development and in many (if not all) different cell lines in culture, including U2OS (Amaar et al., 2002) and fibroblastic cells used in this work. In these cell lines, FHL2 has been reported to localize in several cellular compartments, including focal adhesions (Scholl et al., 2000; Li et al., 2001; Gabriel et al., 2004) , cytoplasm and nucleus (Scholl et al., 2000; Muller et al., 2002; Morlon and Sassone-Corsi, 2003) . This cellular localization and/or expression of FHL2 in these cell lines have been shown to be highly regulated and might be an essential parameter in modulating different cellular functions. Notably, signals, as different as mitogenic restimulation of arrested cells, morphogenic stimulation or cell irradiation, strongly increase FHL2 expression and/or nuclear localization (Muller et al., 2002; Morlon and Sassone-Corsi, 2003; Philippar et al., 2004; Purcell et al., 2004) . Consistent with this observation, the FHL2 gene was shown to be a direct target of both p53 (Scholl et al., 2000) and SRF (Philippar et al., 2004) . Collectively, these data suggest that FHL2 activation might be a general and early response to changes in cellular homeostasis. In some aspects it is similar to activation of NFKB or c-fos, which precedes and synergizes with more specific secondary responses whose outcome is to direct cells either to apoptosis, proliferation or differentiation. It is likely that FHL2 exerts multiple functions upon its translocation into the nucleus where it directly interacts with several transcription factors, including E4F1 and two other kruppel-type zinc-finger transcription factors, the products of the Wilms tumor suppressor gene Wt1 (Du et al., 2002) and the promyelocytic leukemia zinc-finger (plzf) protein (McLoughlin et al., 2002) . In most cases, FHL2 association with transcription factors was shown to result in stimulation of the transcriptional activity of these factors, FHL2 acting either as a coactivator for transactivators or a corepressor for repressors. Ex vivo studies have demonstrated for E4F1 the potential to either repress or activate transcription depending if the protein is full-length (p120) or proteolytically truncated (p50), respectively (Fognani et al., 1993; Fajas et al., 2000 Fajas et al., , 2001 . Our mapping of E4F1-FHL2 interaction shows that FHL2 does not associate with p50 E4F2 , whereas it strongly binds in vitro and in vivo to the repressor p120
E4F1
. Surprisingly, we found that p120 E4F1 transcriptional activity was inhibited by FHL2 rather than enhanced, suggesting that FHL2 acts as an inhibitor for E4F1 rather than as a corepressor. Although atypical, such inhibitory effect of FHL2 has already been reported on the transcription factors SRF (Philippar et al., 2004) , FOXO1 (Yang et al., 2005) and Hand1 (Hill and Riley, 2004) . In the case of SRF, FHL2 was shown to compete for interaction of this factor with the coactivator MAL (Philippar et al., 2004) , whereas it inhibits FOXO1 transcription by recruiting the deacetylase SIRT1 to FOXO1 complexes (Yang et al., 2005) . The molecular mechanism by which FHL2 blocks E4F1 transcriptional activity on cycA-Luc and E4-TK-Luc reporters remains unclear. Indeed, by using a number of assays we found no evidence for an interaction of FHL2 with the DNA binding domain of E4F1 (Figure 2) , an Co-immunoprecipitation of nuclear p53 and E4F1 in presence of FHL2. Nuclear extracts were prepared from U2OS cells transiently co-transfected with combinations of expression vectors encoding HA-tagged E4F1, full-length p53 and Flagged-FHL2, as indicated. E4F1 was immunoprecipitated from these extract using affinity purified polyclonal anti-E4F1 Abs (E4F-AD1 þ E4F-88) or control antibody. These precipitates and one-tenth of the input nuclear extracts were probed for the presence of Ha-tagged-E4F1, Flag-tagged and p53 by immunoblotting using monoclonal anti-Ha, anti-p53 (DO1) and anti-Flag, respectively. in vitro effect of FHL2 on E4F-binding activity to DNA, or direct binding of FHL2 to DNA (Paul and Sardet, unpublished observations). Moreover, we also considered that FHL2 might interfere with the association of E4F1 with the corepressor histone deacetylase HDAC1 (Colombo et al., 2003) , assuming that this would prevent nucleosome deacetylation and transcriptional repression at E4F-regulated promoters. However, we were unable to test this hypothesis because, unlike others (Colombo et al., 2003) , we did not detect E4F-HDAC1 complexes in our cell systems (Paul and Sardet., unpublished observations). A better knowledge of E4F1 communication with the polymerase II holoenzyme and with the chromatin remodeling machinery in U2OS will be required to further explore the mechanisms of this FHL2-mediated inhibition of E4F1 transcriptional activity.
Beside this direct effect on transcription, evidence indicates that E4F1-mediated growth arrest also depends on its association with p53 and pRb (Sandy et al., 2000; Fajas et al., 2000; Rizos et al., 2003) . As previously shown in mouse fibroblasts (Sandy et al., 2000) , we found that ectopically expressed E4F1 and p53 form a nuclear complex in Human U2OS cells and that the growth arrest induced by E4F1 overexpression in these cells is sensitive to ShRNA-mediated depletion of endogenous p53 (Figure 4) . Significantly, ectopic expression of FHL2 antagonizes the formation of these E4F1-p53 nuclear complexes, suggesting that FHL2 also counteracts E4F1 effects on proliferation through the disruption of this complex. Importantly, we did not observe similar effects of FHL2 on E4F1-pRB complexes (Paul and Sardet, unpublished observation). These data suggest that FHL2, upon its nuclear translocation, targets at least two E4F1 functional properties required for growth arrest, that is its association with p53 and its capacity to repress transcription. Notably, others have shown that the FHL2 gene is a transcriptional target of p53 with a kinetics of induction similar to p21 (Scholl et al., 2000) . Consistent with this observation, FHL2 expression is strongly induced in various cell lines (Scholl et al., 2000) and in primary human peripheral blood lymphocytes (PBLs) (Kang et al., 2003) exposed to irradiation, that is under conditions where p53 is stabilized and activated. As shown here in U2OS, and by others in fibroblasts (Morlon and Sassone-Corsi, 2003) , this response of FHL2 to irradiation also occurs at the level of its ) and FHL2 was immunoprecipitated from these extracts using a rabbit polyclonal anti-FHL2 Ab (FHL2-CS1). These FHL2 precipitates (IP a-FHL2) or control immunoprecipitation realized with preimmune serum (IP pre-im) were probed for the presence of E4F1 by immunoblotting using affinity purified polyclonal anti-E4F1 Ab (E4F-AD1). Of the input nuclear extracts, 4%, were probed in each condition (input). nuclear accumulation. Thus, UV irradiation rapidly induces an accumulation of FHL2 in the nucleus with a kinetics that suggests this translocation precedes the stimulation of its expression by p53 (Scholl et al., 2000; Morlon and Sassone-Corsi, 2003) . Interestingly, we observed that this UV-induced nuclear relocalization correlates with the formation of native E4F-FHL2 complexes in U2OS cells. While, these data do not definitively address the physiological function of this targeting it is tempting to speculate that FHL2 could be the effector of a feed back loop controlling of the p53 pathway, whose functions would be to target p53-E4F1 nuclear complexes and E4F1 transcriptional program in response to irradiation. In addition, while there are evidence that E4F1, p53 and FHL2 participate individually in cellular growth control and apoptosis, the role of genuine p53-E4F1 and E4F1-FHL2 complexes in these processes remain to be investigated and will constitute the subject of our future studies.
Materials and methods
DNA plasmids
Details of all constructs are available upon request. Bait for the two-hybrid assays in pPC97 is as follow: pPC97-p120E4F
0 ; pPC97Sal/Bgl2). Mammalian E4F1 expression constructs are in pcDNA3 (Invitrogen, Cergy-Pontoise, France) as follows: pcDNAp120 E4F1 (full-length E4F1), pcDNA-p50 E4F1 (amino-acid (aa)1-357 of E4F1), DDBD-E4F1 (aa357-784 of E4F1) and Gal4-DDBD-E4F1 were previously described in Fajas et al. (2000 Fajas et al. ( , 2001 . Mammalian FHL2 expression constructs are as follows: pCI-FHL2, a 5 0 end Not1/Sal1 fragment from Y2H prey clone pPC86-FHL2 encoding full-length FHL2 was cloned Not1/Sal1 in pCINeo. 3 Â Flagged FHL3 constructs, pCI3XF-FHL2, was constructed by cloning first a single copy of the double-stranded oligonucleotide ( þ ) 5 0 -GGCCGC TAATACGACTCACTATAGGGATGGATTATAAAGAT GATGACGATAAGGATTACAAAGACGATGATGACAA GGACTATAAAGACGACGATGATAAAG-3 0 /(À) 5 0 -AAT TCTTTATCATCGTCGTCTTTATAGTCCTTGTCATCATC GTCTTTGTCATCCTTATCGTCATCATCTTTATAATCC ATCCCTATAGTGAGTCGTATTAGC-3 0 into digested Nhe1/Not1 pCI-FHL2 and by replacing the Not1/Xho1 fragment by a fragment generated by polymerase chain reaction (PCR) ( þ ) 5 0 -CTGACGCGGCCGCTGACTGAGC GCTTTGACTGCCAC-3 0 and with the commun minus strand (À) 5 0 -CTGACCTCGAGTCAGATGTCTTTCCCACAGT CG-3 0 . FHL2 deletion constructs were built using similar strategy: pCI3XF-FHL2DL1, ( þ ) 5 0 -CTGACGCGGCCGCT GTTTGAGACCCTGTTCGCCAACAC-3 0 and the commun minus strand; pCI3XF-FHL2DL1/L2, ( þ ) 5 0 -CTGACGCG GCCGCTGTATTCCAACGAGTACTCATCCAAG-3 0 and minus commun strand; pCI3XF-FHL2DL1/L2/L3, ( þ ) 5 0 -CTGACGCGGCCGCTGTATGAGAAACAACATGCCATG CAG-3 0 and minus commun strand. Reporter constructs, E4-TK-LUC, pCycA-DCCRE/CHR-Luc and CMV-GFP were as previously described (Fajas et al., 2000 (Fajas et al., , 2001 . FHL2 GST fusion (pGKG-FHL2) was constructed by cloning a fragment Bam1/Xho1 from pCINeoFHL2 in pGEX-KG (BamH1/ Xho1). Plasmid that direct the synthesis of shRNA directed to human p53 is as described in Brummelkamp et al. (2002) .
Two-hybrid screening
Yeast strain MAV103 expressing pPC97-p120 E4F1 was transfected with a WI38 human fibroblasts cDNA pPC86 preys library and interactors were selected essentially as previous described (Sardet et al., 1995; Fajas et al., 2000) .
Cell culture, transfections and luciferase assays U2OS osteosarcoma cells line and RDE human embryonal rhabdomyosarcoma cells line were grown in Dulbecco modified Eagle medium (Sigma, Saint Quentin Fallavier, France) supplemented with 10% FBS. All transfections were carried out using calcium phosphate procedure. For E4F1/ FHL2 Luciferase assays, cells were co-transfected with 0.2 mg of pCH110b-galactosidase expression vector and 2 mg of E4-TK-LUC or pCycA-DCCRE/CHR-Luc alone or with various combinations of 100 ng of pcDNA-p120 E4F1 , pCI3XF-FHL2 or pCI3XF-FHL2DL1/L2/L3. b-Galactosidase and luciferase activity were measured 36 h later as previously described (Fajas et al., 2000 (Fajas et al., , 2001 . Luciferase activity values were normalized to the b-galactosidase activity to account for variations in transfection efficiencies. FHL2
À/À pR 53 and WTpR 53 3T3 mouse fibroblasts were derived from FHL2
À/À and control WT 3T3 cells (Labalette and Wei, 2004) to contain a retrovirally transduced, functional p53 protein.
Immunofluorescence U2OS and RDE cells were grown on coverslips for 24 h and transfected for 10 h with indicated plasmids and further grown for 20 h before different treatment of cells. For BrdU staining, cells were incubated for 5 h with BrdU. After formalin fixation for 20 min at 41C followed by a 5 min methanol permeabilization, cells were treated with 2 N HCl for 15 min at room temperature and incubated with anti-BrdU mouse monoclonal antibody (Immunotech-Beckman Coulter, Luminy, France). Apoptosis analysis was performed with In Situ Cell Death Detection Kit, TMR red following the manufacturer's instructions (Roche, Penzberg, Germany). Detection of transfected FHL2 was performed with anti-FLAG primary monoclonal anti-body M2 (Sigma-Aldrich, Saint Quentin Fallavier, France) and that of endogenous FHL2 with a goat anti-FHL2 (Santa Cruz via tebu-bio, le Perray en Yvelines, France), followed by incubation with suitable Texas-redlabeled secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, USA). Detection of E4F1 was as described previously (Fajas et al., 2000 (Fajas et al., , 2001 .
Glutathione S-transferase pull-down assay, protein extracts, immunoprecipitations. Glutathione S-transferase pull-down assays were carried out with similar amounts of GST, GST-ELK and GST-FHL2 proteins bound to Gluthatione-sepharose Beads (Amersham-GE HealthCare Biosciences, Orsay, France) combined with 35 S-labeled in vitro translated fulllength E4F1 in PBST (PBS with 0.1% Tween, 20 mM ZnSO 4 ). For co-immunoprecipitation of transfected p53-E4F1, FHL2-E4F1 complexes, U2OS cells were transfected with indicated expression plasmids (pCMV-p53, pCI3XF-FHL2, pCDNA3-E4F1, pCI3XF-FHL2 or FHL2 and E4F1 deletions) and used to prepare nuclear extracts as previously described (Fajas et al., 2000 (Fajas et al., , 2001 . Immunoprecipitations were carried on 1 mg of nuclear extracts with either a mixture of rabbit anti-E4F1 polyclonal antibodies (AD1 and 88-2, Fajas et al., 2000 Fajas et al., , 2001 , anti-Flag (Sigma-Aldrich) or anti-HA Igs.ProtA/G-sepharose precipitates (Amersham) were eluted and separated on 10% acrylamide sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS/PAGE) gels, blotted and probed with either anti-E4F1 polyclonal antibody (p120lyon, Fajas et al., 2000 Fajas et al., , 2001 , Anti-p53 (DO1), Anti-FLAG M2 (Sigma-Aldrich) or Anti-TBP (Dantonel et al., 2000) as indicated in figures. For detection of endogenous E4F1-FHL2 complexes in RDE and U2OS cells, nuclear extracts were prepared 4 h after UVC irradiation (30 J/m 2 Amersham), immunoprecipitated with a purified rabbit polyclonal anti-FHL2 developed in the lab (J81, generated against GST-FHL2) or corresponding preimmune serum, and precipitates were probed by Western blot with anti-E4F1. For FHL2 localization, 20 mg of nuclear and cytosolic extract prepared as described (Fajas et al., 2000 (Fajas et al., , 2001 and probed by Western blotting with indicated Igs.
